Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use

Background: We evaluated feasibility, safety, and total resource use of subcutaneous immunoglobulin (SCIG) in a pilot study of patients who underwent allogeneic hematopoietic cell transplant (HCT) over a 6-month period. Methods: A total of 20 eligible patients were treated with SCIG at 0.1 g/kg/week...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Ivan Pasic, Wael Alanazi, George Dranitsaris, Lani Lieberman, Auro Viswabandya, Dennis Dong Hwan Kim, Jeffrey H. Lipton, Fotios V. Michelis
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wolters Kluwer Medknow Publications 2021-10-01
Serie:	Hematology/Oncology and Stem Cell Therapy
Soggetti:	allogeneic hematopoietic cell transplant feasibility hypogammaglobulinemia pilot study subcutaneous immunoglobulin
Accesso online:	https://journals.lww.com/10.1016/j.hemonc.2021.01.001
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!